Baseline characteristics of propensity score-matched patients with PF-ILD at PF-ILD diagnosis
| PF-ILD | ||||||||
| IPF | Non-IPF | |||||||
| Matched total (n=36) | Matched antifibrotic (n=18) | Matched no-antifibrotic (n=18) | P value | Matched total (n=64) | Matched antifibrotic (n=32) | Matched no-antifibrotic (n=32) | P value | |
| Characteristics | ||||||||
| Sex, male | 30 (83.33)* | 3 (16.67) | 3 (16.67) | 1.000 | 44 (68.75) | 21 (65.63)* | 23 (71.88) | 0.7879 |
| Age (years) | 72.5 (69–75.75) | 71 (67.75–76) | 74 (69.75–78.5) | 0.3939 | 71 (64–74) | 71 (61.25–74) | 71 (64–73) | 0.7165 |
| BMI | 23.27 (21.40–25.15) | 22.31 (19.60–25.22) | 23.79 (21.91–25.10) | 0.2503 | 22.79 (21.19–25.41) | 22.70 (20.84–28.39) | 23.76 (21.71–25.48) | 0.6371 |
| Serological examination | ||||||||
| Monocyte count | 443.4 (352.2–578) | 525.9 (375.6–604.4) | 439.1 (339.3–551.4) | 0.2466 | 435.4 (349.1–570.4) | 435.4 (380.6–553.4) | 436.5 (307.9–604.5) | 0.7890 |
| LDH | 211 (184.5–265) | 210 (184.3–266.3) | 217 (188.5–265) | 0.8148 | 215 (184.5–245.8) | 211 (175.8–239.5) | 223 (1882.5–255.5) | 0.3901 |
| KL-6 | 1087 (684.3–1644.8) | 992 (696.3–1690.4) | 1120.7 (614.5–1616.4) | 0.9139 | 840.5 (592.7–1311.7) | 805.5 (598.9–1311.7) | 924.5 (454.6–1440.3) | 0.8658 |
| CRP | 0.22 (0.1–0.49) | 0.23 (0.1–0.53) | 0.16 (0.1–0.46) | 0.9620 | 0.15 (0.1–0.35) | 0.17 (0.1–0.35) | 0.13 (0.05–0.35) | 0.3460 |
| Pulmonary function | ||||||||
| FVC | 2.34 (1.94–2.95) | 2.34 (2.02–2.97) | 2.48 (1.88–2.96) | 0.9725 | 2.26 (1.73–2.92) | 2.27 (1.84–2.78) | 2.25 (1.73–3.07) | 0.6182 |
| %FVC | 83.8 (71.5–91.33) | 84.85 (72.78–90.93) | 83.8 (70.33–91.75) | 0.8207 | 79.1 (64.2–90.4) | 79.3 (62.2–90.4) | 78.5 (65.6–89.43) | 0.6028 |
| DLCO (n=74) | 8.73 (7.18–11.08) | 10.42 (7.7–11.19) | 8.13 (7.07–10.36) | 0.5093 | 9.13 (7.37–11.68) | 9.05 (7.32–11.71) | 10.07 (7.35–11.85) | 0.7696 |
| %DLCO (n=74) | 56.6 (45.88–76.9) | 62.26 (48.45–77.81) | 55.6 (45.45–75.74) | 0.5184 | 56.8 (42.4–71.75) | 51.64 (40.48–72.65) | 60.9 (43.5–71.6) | 0.7720 |
| Radiological findings | ||||||||
| Honeycombing | 24 (66.67) | 13 (72.22) | 11 (61.11) | 0.7247 | 19 (29.69) | 10 (31.25) | 9 (28.13) | 1.000 |
| Traction bronchiectasis | 20 (55.56) | 9 (50.0) | 11 (61.11) | 0.7380 | 44 (68.75) | 21 (65.63) | 23 (71.88) | 0.7879 |
| Immunosuppressive agents | ||||||||
| Glucocorticoids (PSL<10 mg/day) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1.000 | 5 (6.80) | 3 (9.38) | 2 (6.25) | 1.000 |
| Glucocorticoids (PSL≥10 mg/day) | 7 (19.44) | 4 (22.22) | 3 (16.67) | 1.000 | 10 (15.63) | 4 (12.5) | 6 (18.75) | 0.7323 |
| Immunosuppressant | 2 (5.56) | 1 (5.56) | 1 (5.56) | 1.000 | 11 (17.19) | 6 (18.75) | 5 (15.63) | 1.000 |
*Data are shown as n (%) or median (IQR).
BMI, body mass index; CRP, C-reactive protein; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; KL-6, sialylated carbohydrate antigen Krebs von den Lungen-6; LDH, lactate dehydrogenase; PF-ILD, progressive fibrosing interstitial lung disease; PSL, prednisolone.